Skip to main content
. 2022 Nov 21;10(1):e200056. doi: 10.1212/NXI.0000000000200056

Figure 2. Risk of Clinical Relapse and/or Contrast-Enhancing Lesion Occurrence in Relation to Time Since Last Rituximab Infusion.

Figure 2

(A) Kaplan-Meier curve of event-free time since last rituximab infusion. (B) Incidence rate of clinical relapse and/or CELs at <8 months, ≥8 to 12, ≥12 to 18, and ≥18 months since last rituximab infusion. CEL = contrast-enhancing lesion; RTX = rituximab.